

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Tirzepatide for treating type 2 diabetes

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| None identified. |

- | |
|---|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| Diabetes UK identified the following equality issues: <ul style="list-style-type: none">• people of South Asian, Black Caribbean, Black African and South Asian family background are at a higher risk of being diagnosed with type 2 diabetes, and at a younger age.• there is a higher prevalence of the condition among people in more deprived areas and they have poorer care, leading to poorer outcomes.• a high proportion of people with type 2 diabetes have excess weight. People who experience weight stigma are less likely to have good care and to seek help from a healthcare professional to support weight loss. The committee noted these concerns, but concluded that they had no effect on its recommendations. |

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?
No other equality issues were identified.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
No.

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
Yes, in section 3.21

Approved by Associate Director (name):

Date: 21 August 2023

Final appraisal determination

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?
None identified.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?
No.

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
Yes, in section 3.19

Approved by Associate Director (name): ...Janet Robertson...

Date: 31/08/2023